Structured evidence table for Potassium Blood Pressure Meta-Analysis, generated from 4 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Potassium Blood Pressure Meta-Analysis | This phenotype is associated with higher risks of stroke, heart failure, chronic kidney disease, and death. | 1 | Falodia Rahul (2026) | Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials |
| Potassium Blood Pressure Meta-Analysis | In the phase 2 BrigHTN trial, baxdrostat reduced seated systolic BP by 8–11 mmHg versus placebo at 12 weeks in resistant hypertension, without adrenocortical insufficiency or serious drug‐related events []. | 1 | Falodia Rahul (2026) | Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials |
| Potassium Blood Pressure Meta-Analysis | 17 2 Risk of bias was assessed independently by two reviewers using the Cochrane Risk of Bias tool version 2.0 (RoB 2) across five domains: (1) randomization process; (2) deviations from intended interventions; (3) missing outcome data; (4) measurement of outcome; and (5) selection of the reported result []. | 1 | Falodia Rahul (2026) | Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials |
| Potassium Blood Pressure Meta-Analysis | 1 2 3 4 5 Hypertension is the most common modifiable cause of cardiovascular death worldwide, yet many patients do not achieve target blood pressure despite multidrug therapy [,,]. | 1 | Falodia Rahul (2026) | Efficacy and Safety of Baxdrostat for Hypertension: A Systematic Review and Meta‐Analysis of Three Phase 2/3 Randomized Controlled Trials |
| Potassium Blood Pressure Meta-Analysis | A meta-analysis of 91 studies from 1991–2017 with over 3 million treated hypertensive patients found true-RH prevalence to be 10.3%.The pathophysiology of RH is multifactorial and not fully understood. | 1 | Kamrul-Hasan A.B.M. (2026) | Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | 7 [] 2 [] 8 [] 9 [] 10 [] Excess aldosterone promotes inflammation, vascular changes, and tissue fibrosis linked to cardiometabolic diseases.Due to its high prevalence as a cause of poor BP control, current RH guidelines recommend MRAs after 3 antihypertensives, though side effects, especially antiandrogenic ones, often limit use.The emerging role of aldosterone-targeted therapies, including ASIs, is promising. | 1 | Kamrul-Hasan A.B.M. (2026) | Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | 14 [] 2 P All statistical analyses were conducted using the Review Manager (RevMan) computer program, version 7.2.0.The results of the outcomes were expressed as mean differences (MDs) for continuous variables and risk ratios (RRs) for dichotomous variables with 95% confidence intervals (CIs). | 1 | Kamrul-Hasan A.B.M. (2026) | Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | Key mechanisms include excessive sodium retention, obesity, an overactive sympathetic nervous system, drug use for other conditions, and inappropriate activation of the renin-angiotensin-aldosteronesystem (RAAS).RH is strongly linked to adverse health outcomes, especially cardiovascular events and chronic kidney disease. | 1 | Kamrul-Hasan A.B.M. (2026) | Safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled hypertension: A systematic review and meta-analysis |
| Potassium Blood Pressure Meta-Analysis | Background Non-adherence to dietary and fluid restrictions among dialysis patients is associated with adverse clinical outcomes. | 1 | Sarmadi S (2026) | The effect of nutrition education interventions on dialysis patients' outcomes: a systematic review and meta-analysis. |
| Potassium Blood Pressure Meta-Analysis | Risk of bias was assessed using RoB-2 and ROBINS-I, certainty graded using GRADE, and random-effects meta-analyses conducted alongside subgroup, sensitivity, and meta-regression analyses. | 1 | Sarmadi S (2026) | The effect of nutrition education interventions on dialysis patients' outcomes: a systematic review and meta-analysis. |
| Potassium Blood Pressure Meta-Analysis | Nutrition education significantly improved knowledge (SMD = 1.09; 95% CI: 0.67-1.51) and health-related quality of life (SMD = 1.43; 95% CI: 0.86-2.00; I² = 0%), and reduced serum potassium (SMD = -0.52; 95% CI: -0.91 to -0.14; I² = 92%) and serum phosphate (SMD = -0.35; 95% CI: -0.56 to -0.15; I² = 81%). | 1 | Sarmadi S (2026) | The effect of nutrition education interventions on dialysis patients' outcomes: a systematic review and meta-analysis. |
| Potassium Blood Pressure Meta-Analysis | Quantifying the effectiveness of nutrition education interventions can inform practice and policy. | 1 | Sarmadi S (2026) | The effect of nutrition education interventions on dialysis patients' outcomes: a systematic review and meta-analysis. |
Source documents